Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

656 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical prognosis in BRAF-mutated PTC.
Puxeddu E, Moretti S. Puxeddu E, et al. Among authors: moretti s. Arq Bras Endocrinol Metabol. 2007 Jul;51(5):736-47. doi: 10.1590/s0004-27302007000500011. Arq Bras Endocrinol Metabol. 2007. PMID: 17891237 Review.
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F. Puxeddu E, et al. Among authors: moretti s. J Clin Endocrinol Metab. 2004 May;89(5):2414-20. doi: 10.1210/jc.2003-031425. J Clin Endocrinol Metab. 2004. PMID: 15126572
Targeted molecular therapies in thyroid carcinoma.
Romagnoli S, Moretti S, Voce P, Puxeddu E. Romagnoli S, et al. Among authors: moretti s. Arq Bras Endocrinol Metabol. 2009 Dec;53(9):1061-73. doi: 10.1590/s0004-27302009000900002. Arq Bras Endocrinol Metabol. 2009. PMID: 20126863 Review.
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R. Fugazzola L, et al. Among authors: moretti s. Endocr Relat Cancer. 2006 Jun;13(2):455-64. doi: 10.1677/erc.1.01086. Endocr Relat Cancer. 2006. PMID: 16728573
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. Durante C, et al. Among authors: moretti s. J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3. doi: 10.1210/jc.2006-2707. Epub 2007 May 8. J Clin Endocrinol Metab. 2007. PMID: 17488796
Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E. Carta C, et al. Among authors: moretti s. Clin Endocrinol (Oxf). 2006 Jan;64(1):105-9. doi: 10.1111/j.1365-2265.2005.02401.x. Clin Endocrinol (Oxf). 2006. PMID: 16402937
656 results